Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase I/II study of nicotinamide riboside (NR) in patients with Cockayne Syndrome

Next Previous
X
Search
Trial Profile

A phase I/II study of nicotinamide riboside (NR) in patients with Cockayne Syndrome

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 24 Nov 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nicotinamide riboside (Primary)
  • Indications Cockayne syndrome
  • Focus Adverse reactions

    • Most Recent Events

    • 24 Nov 2016 New trial record
    • 11 Nov 2016 According to a Chroma Technology Corporation media release, the company anticipates to file an investigational new drug application for the initiation of this trial in the first quarter of 2017. The FDA has indicated it will consider a Fast Track designation for nicotinamide riboside at the time of the IND submission.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top